Professor. Robert Frenck is a Professor of Pediatrics in the Division of Infectious Diseases at Cincinnati Children’s Hospital Medical Center (CCHMC). He earned a BA in Biology from the University of California at San Diego and his medical degree at the University of Texas Health Science Center at Houston (UTHSC). He completed a residency in Pediatrics at the National Naval Medical Center in Bethesda, Maryland, and a fellowship in Pediatric Infectious Diseases at UTHSC. Professor Frenck is the Director of the James Gamble Center for Vaccine Research at CCHMC, as well as the Principal Investigator (PI) of the National Institutes of Health (NIH)-funded Vaccine and Treatment Evaluation Unit (VTEU) at CCHMC. He is a recognized expert in conducting clinical trials, with particular emphasis on enteric diseases, and has published over 125 manuscripts in the peer-reviewed literature. Professor Frenck was the site PI for the Phase 1 Pfizer/BioNTech SARS-CoV-2 vaccine as well as one of five investigators in the US evaluating the SARS-CoV-2 vaccine in adolescents. As part of Operation Warp Speed, Professor Frenck is currently the site PI for the AstraZeneca SARS-CoV-2 vaccine.